| Dr Jhoette Archein Magaway Dumlao, MD | |
|
1806 W Lincoln Ave, Yakima, WA 98902-2473 | |
| (509) 452-4946 | |
| (509) 457-3989 |
| Full Name | Dr Jhoette Archein Magaway Dumlao |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 17 Years |
| Location | 1806 W Lincoln Ave, Yakima, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104110105 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | ML60231264 (Washington) | Secondary |
| 207Q00000X | Family Medicine | MD60408621 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nova Home Hospice Inc | Upland, CA | Hospice |
| Anthem Hospice Providers Inc | Colton, CA | Hospice |
| Compassion Hospice & Palliative Care | Colton, CA | Hospice |
| Chino Valley Medical Center | Chino, CA | Hospital |
| Montclair Hospital Medical Center | Montclair, CA | Hospital |
| Park Avenue Healthcare & Wellness Center | Pomona, CA | Nursing home |
| Chino Valley Health Care Cente | Pomona, CA | Nursing home |
| Jurupa Hills Post Acute | Riverside, CA | Nursing home |
| Corona Health Care Center | Corona, CA | Nursing home |
| Inland Valley Care And Rehabilitation Center | Pomona, CA | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Epic Medical Group,inc | 4385883958 | 41 |
| Community Care Mobile Doctors | 8325428857 | 3 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Beaver Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649503319 PECOS PAC ID: 0547164295 Enrollment ID: O20031124000449 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Desert Valley Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639117864 PECOS PAC ID: 4880595875 Enrollment ID: O20040113000803 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Hospitalist Medicine Physicians Of California Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184663965 PECOS PAC ID: 8426062027 Enrollment ID: O20060202000956 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Epic Medical Group,inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295178689 PECOS PAC ID: 4385883958 Enrollment ID: O20130612000470 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Inpatient Specialists Of California Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952792475 PECOS PAC ID: 3476864448 Enrollment ID: O20150617000915 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Hospitalist Medicine Physicians Of California - Apple Valley, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447738075 PECOS PAC ID: 2567715972 Enrollment ID: O20181101002570 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Entity Name | Community Care Mobile Doctors |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750029690 PECOS PAC ID: 8325428857 Enrollment ID: O20220630001170 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jhoette Archein Magaway Dumlao, MD 1806 W Lincoln Ave, Yakima, WA 98902-2473 Ph: (509) 452-4946 | Dr Jhoette Archein Magaway Dumlao, MD 1806 W Lincoln Ave, Yakima, WA 98902-2473 Ph: (509) 452-4946 |
News Archive
Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has been granted a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on November 22nd, 2011 to discuss the initial clinical development plan for ADXS-HER2, a construct for the treatment of HER2 expressing cancers.
ActiveRx Rehabilitation, a Chandler, Arizona-based wellness-oriented rehabilitation company specializing in active aging, is introducing a breakthrough Fall Risk Assessment and Fall Prevention Program for Medicare-eligible senior patients.
As a result of improved imaging technology, pancreatic cysts are increasingly diagnosed in asymptomatic individuals who undergo scans for other reasons. And while most of these cysts follow a benign course, a small but significant number are either malignant at the time of diagnosis or have the potential to develop into pancreatic cancer during a patient's lifetime.
Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH - the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine and aspartate aminotransferases, hepatic enzymes that indicate cell damage.
› Verified 3 days ago
Dr. Stephen G Litchfield, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 210 S 11th Ave, Suite 44, Yakima, WA 98902 Phone: 509-248-4586 Fax: 509-576-8857 | |
Dr. Sheau-fang Pan, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1806 W Lincoln Ave, Yakima, WA 98902 Phone: 509-452-4520 Fax: 509-452-5224 | |
Dr. Eve K Barker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1806 W Lincoln Ave, Yakima, WA 98902 Phone: 509-452-4520 Fax: 509-452-5224 | |
Paul E Emmans Jr., D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 402 S 12th Ave, Yakima, WA 98902 Phone: 509-574-6139 Fax: 509-574-6138 | |
Dr. Duane Eugene Teerink, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 311 S 72nd Ave, Yakima, WA 98908 Phone: 509-972-1818 Fax: 509-225-2706 | |
Michael Jach, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 602 E Nob Hill Blvd, Yakima, WA 98901 Phone: 509-248-3334 Fax: 509-453-6144 | |
Dr. Mia-anne Paolucci, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 1806 W Lincoln Ave, Yakima, WA 98902 Phone: 509-452-4520 |